Atopic Dermatitis (Eczema) clinical trials at UCSF
7 in progress, 4 open to eligible people
Allergic Disease Onset Prevention Study
open to all eligible people
This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1 hypersensitivity). Subjects will be enrolled in a three-part sequential approach. Participants in the safety-run portion of the study (Part A1: 1 year to <6 years of age and A2: 1 month to <12 months of age) will receive 28 days of treatment with STMC-103H or placebo, followed by 28 days of follow-up. A Data and Safety Monitoring Committee (DSMC) will review safety data after all patients in each part complete 28 days of therapy prior to enrolling the next part. After A2, Part B will enroll 224 patients for 336 days of treatment with STMC-103H or placebo, followed by 336 days of follow-up. Stool, blood, and optional samples will be collected in Parts A2 and part B. Primary safety endpoints are frequency, type and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), as well as findings on physical exams, vitals, and safety laboratories. The primary efficacy endpoint is incidence of physician-diagnosed atopic dermatitis at day 336.
San Francisco, California and other locations
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
open to eligible people ages 18 years and up
This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.
San Francisco, California
Molecular Signatures of Cutaneous Dupilumab Response
open to eligible people ages 18 years and up
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
San Francisco, California
Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use
open to eligible people ages 13 years and up
Design and beta-test a research-oriented mobile health app to assess disease activity, quality of life, treatment patterns, adverse medication effects, and lifestyle factors in patients with atopic dermatitis.
San Francisco, California
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Sorry, not currently recruiting here
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
San Francisco, California and other locations
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Sorry, not currently recruiting here
The primary objective of the study is: • To describe further the efficacy of dupilumab on extent and severity of eczematous lesions in skin of color participants, at least (≥)12 years old, with moderate-to-severe atopic dermatitis (AD) The secondary objectives of the study are: - To describe further the efficacy of dupilumab on pruritus and other AD symptoms in skin of color participants, ≥12 years old, with moderate-to-severe AD - To describe further the efficacy of dupilumab on measures of mental health (anxiety and depression) and quality of life (QOL) in skin of color participants, ≥12 years old, with moderate-to-severe AD - To describe further the safety of dupilumab administered to skin of color participants, ≥12 years old, with moderate-to-severe AD - To assess dupilumab modulation of type 2 biomarkers in skin of color participants, ≥12 years old, with moderate-to-severe AD - To evaluate further the systemic exposure of dupilumab in skin of color participants, ≥12 years old, with moderate-to-severe AD
San Francisco, California and other locations
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
Sorry, in progress, not accepting new patients
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.
Fresno, California and other locations
Our lead scientists for Atopic Dermatitis (Eczema) research studies include Morna Dorsey, MD Jeffrey Cheng, MD, PhD Wilson Liao Tina Bhutani.
Last updated: